


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) Compounds of general formula I



in which

- A stands for C₃-C₁₂-arylene or C₃-C₁₈-heteroarylene,
- B stands for a bond or for C₁-C₁₂-alkylene, C₂-C₁₂-alkenylene, C₂-C₁₂-alkinylene, C₃-C₈-cycloalkylene, C₃-C₁₂-heterocycloalkylene, C₃-C₁₂-arylene or C₃-C₁₈-heteroarylene that is optionally substituted in one or more places in the same way or differently with hydroxy, halogen, cyano, nitro, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkinyl, C₃-C₁₀-cycloalkyl, C₁-C₆-hydroxyalkyl, C₃-C₁₂-aryl, C₃-C₁₈-heteroaryl, -(CH₂)_p-C₃-C₁₂-aryl, -(CH₂)_p-C₃-C₁₈-heteroaryl, phenyl-(CH₂)_p-R¹⁰, -(CH₂)_pPO₃(R¹⁰)₂,

$-(CH_2)_pSO_3R^8$, or with the group $-NR^8R^9$, $-NR^8COR^9$, $-NR^8CSR^9$,
 $-NR^8SOR^9$, $-NR^8SO_2R^9$, $-NR^8CONR^9R^{10}$, $-NR^8COOR^9$,
 $-NR^8C(NH)NR^9R^{10}$, $-NR^8CSNR^9R^{10}$, $-NR^8SONR^9R^{10}$,
 $-NR^8SO_2NR^9R^{10}$, $-COR^8$, $-CSR^8$, $-S(O)R^8$, $-S(O)_2R^8$,
 $-S(O)_2NR^8R^9$, $-SO_3R^8$, $-CO_2R^8$, $-CONR^8R^9$, $-CSNR^8R^9$, $-SR^8$ or
 $-CR^8(OH)-R^9$,

X and Y, in each case independently of one another, stand for oxygen, sulfur or

for the group $=NR^{11}-$, $-NR^{11}(CH_2)-$, $-NR^{11}O-$, $-ONR^{11}-$, $=CR^6R^7$, $=C=O$, $=C=S$,
 $=SO$, $=SO_2$, $-C(O)O-$, $-OC(O)-$, $-S(O)O-$, $-OS(O)-$, $-S(O)_2O-$,
 $-OS(O)_2-$, $-CONR^8-$, $-N(COR^8)-$, $-N(COOR^8)-$, $-N(CONR^8R^9)-$, $-NR^8CO-$, $-$
 $OCONR^8-$, $-NR^8C(O)O-$, $-CSNR^8-$, $-NR^8CS-$, $-OCSNR^8-$, $-NR^8CSO-$,
 $-SONR^8-$, $-NR^8SO-$, $-SO_2NR^8-$, $-S(O)_2N(COR^8)-$, $-NR^8SO_2-$,
 $-NR^8CONR^9-$, $-NR^8CSNR^9-$, $-NR^8SONR^9-$, $-NR^8SO_2NR^9-$,
 $-NR^8C(O)NR^9-$ or $-NR^8C(S)NR^9-$,

R^1 and R^5 , in each case independently of one another, stand for hydrogen,

hydroxy, halogen, nitro, cyano, C_1-C_6 -alkyl, C_1-C_6 -alkenyl, C_1-C_6 -alkinyl, C_3-C_{10} -cycloalkyl, C_3-C_{12} -aryl, C_3-C_{18} -heteroaryl or for the group $-C_1-C_6$ -alkyloxy- C_1-C_6 -alkyloxy, $-(CH_2)_p-C_3-C_{12}$ -aryl, $-(CH_2)_p-C_3-C_{18}$ -heteroaryl, phenyl- $(CH_2)_p-R^{10}$, $-(CH_2)_pPO_3(R^{10})_2$, $-NR^8R^9$, $-NR^8COR^9$, $-NR^8CSR^9$,
 $-NR^8SOR^9$, $-NR^8SO_2R^9$, $-NR^8CONR^9R^{10}$, $-NR^8COOR^9$,
 $-NR^8C(NH)NR^9R^{10}$, $-NR^8CSNR^9R^{10}$, $-NR^8SONR^9R^{10}$, $-NR^8SO_2NR^9R^{10}$, $-COR^8$,
 $-CSR^8$, $-S(O)R^8$, $-S(O)(NH)R^8$, $-S(O)_2R^8$, $-S(O)_2NR^8R^9$, $S(O)_2N=CH-NR^8R^9$, $-$

SO_3R^8 , $-\text{CO}_2\text{H}$, $-\text{CO}_2\text{R}^8$, $-\text{CONR}^8\text{R}^9$, $-\text{CSNR}^8\text{R}^9$,
 $-\text{SR}^8$ or $-\text{CR}^8(\text{OH})\text{-R}^9$, or for $\text{C}_1\text{-C}_{10}\text{-alkyl}$, $\text{C}_2\text{-C}_{10}\text{-alkenyl}$, $\text{C}_2\text{-C}_{10}\text{-alkinyl}$,
 $\text{C}_3\text{-C}_{10}\text{-cycloalkyl}$, $\text{C}_3\text{-C}_{12}\text{-aryl}$ or $\text{C}_3\text{-C}_{18}\text{-heteroaryl}$ that is substituted in one or
more places in the same way or differently with hydroxy, $\text{C}_1\text{-C}_6\text{-alkoxy}$, halogen,
phenyl or with the group $-\text{NR}^3\text{R}^4$, and the phenyl, $\text{C}_3\text{-C}_{10}\text{-cycloalkyl}$, $\text{C}_3\text{-C}_{12}\text{-aryl}$,
 $\text{C}_3\text{-C}_{18}\text{-heteroaryl}$, $-(\text{CH}_2)_p\text{-C}_3\text{-C}_{12}\text{-aryl}$ and
 $-(\text{CH}_2)_p\text{-C}_3\text{-C}_{18}\text{-heteroaryl}$ itself optionally can be substituted in one or more
places in the same way or differently with halogen, hydroxy, $\text{C}_1\text{-C}_6\text{-alkyl}$, $\text{C}_1\text{-C}_6\text{-alkoxy}$,
or with the group $-\text{CF}_3$ or $-\text{OCF}_3$, and the ring of the $\text{C}_3\text{-C}_{10}\text{-cycloalkyl}$ and
the $\text{C}_1\text{-C}_{10}\text{-alkyl}$ optionally can be interrupted by one or more nitrogen, oxygen
and/or sulfur atoms and/or can be interrupted by one or more $=\text{C=O}$ groups in the
ring and/or optionally one or more possible double bonds can be contained in the
ring,

R^2 stands for hydrogen or $\text{C}_1\text{-C}_{10}\text{-alkyl}$,

R^3 stands for hydrogen, halogen, nitro, cyano, $\text{C}_1\text{-C}_{10}\text{-alkyl}$, $\text{halo-C}_1\text{-C}_{10}\text{-alkyl}$, $\text{C}_2\text{-C}_{10}\text{-alkenyl}$, $\text{C}_2\text{-C}_{10}\text{-alkinyl}$, $\text{C}_3\text{-C}_{10}\text{-cycloalkyl}$, hydroxy, $\text{C}_1\text{-C}_6\text{-alkoxy}$, $\text{C}_1\text{-C}_6\text{-alkylthio}$, amino, $-\text{NH}-(\text{CH}_2)_p\text{-C}_3\text{-C}_{10}\text{-cycloalkyl}$, $\text{C}_1\text{-C}_6\text{-hydroxyalkyl}$, $\text{C}_1\text{-C}_6\text{-alkoxy-C}_1\text{-C}_6\text{-alkyl}$, $\text{C}_1\text{-C}_6\text{-alkoxy-C}_1\text{-C}_6\text{-alkoxy-C}_1\text{-C}_6\text{-alkyl}$, $-\text{NHC}_1\text{-C}_6\text{-alkyl}$, $-\text{N}(\text{C}_1\text{-C}_6\text{-alkyl})_2$, $-\text{SO}(\text{C}_1\text{-C}_6\text{-alkyl})$, $-\text{SO}_2(\text{C}_1\text{-C}_6\text{-alkyl})$, $\text{C}_1\text{-C}_6\text{-alkanoyl}$, $-\text{CONR}^8\text{R}^9$, $-\text{COR}^{10}$, $\text{C}_1\text{-C}_6\text{-alkylOAc}$, carboxy, $\text{C}_3\text{-C}_{12}\text{-aryl}$, $\text{C}_3\text{-C}_{18}\text{-heteroaryl}$, $-(\text{CH}_2)_p\text{-C}_3\text{-C}_{12}\text{-aryl}$, $-(\text{CH}_2)_p\text{-C}_3\text{-C}_{18}\text{-heteroaryl}$, phenyl- $(\text{CH}_2)_p\text{-R}^{10}$, $-(\text{CH}_2)_p\text{PO}_3(\text{R}^{10})_2$ or for the group $-\text{NR}^8\text{R}^9$,

or for C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkinyl, C₃-C₁₀-cycloalkyl, C₃-C₁₂-aryl or C₃-C₁₈-heteroaryl that is substituted in one or more places in the same way or differently with hydroxy, halogen, C₁-C₆-alkoxy, C₁-C₆-alkylthio, amino, cyano, C₁-C₆-alkyl, -NH-(CH₂)_p-C₃-C₁₀-cycloalkyl, C₃-C₁₀-cycloalkyl, C₁-C₆-hydroxyalkyl, C₂-C₆-alkenyl, C₂-C₆-alkinyl, C₁-C₆-alkoxy-C₁-C₆-alkoxy-C₁-C₆-alkyl, -NHC₁-C₆-alkyl, -N(C₁-C₆-alkyl)₂, -SO(C₁-C₆-alkyl), -SO₂(C₁-C₆-alkyl), C₁-C₆-alkanoyl, -CONR⁸R⁹, -COR¹⁰, C₁-C₆-alkylOAc, carboxy, C₃-C₁₂-aryl, C₃-C₁₈-heteroaryl, -(CH₂)_p-C₃-C₁₂-aryl, -(CH₂)_p-C₃-C₁₈-heteroaryl, phenyl-(CH₂)_p-R¹⁰, -(CH₂)_pPO₃(R¹⁰)₂ or with the group -NR⁸R⁹, and the phenyl, C₃-C₁₀-cycloalkyl, C₃-C₁₂-aryl, C₃-C₁₈-heteroaryl, -(CH₂)_p-C₃-C₁₂-aryl and -(CH₂)_p-C₃-C₁₈-heteroaryl itself optionally can be substituted in one or more places in the same way or differently with halogen, hydroxy, C₁-C₆-alkyl, C₁-C₆-alkoxy, or with the group -CF₃ or -OCF₃, and the ring of the C₃-C₁₀-cycloalkyl and the C₁-C₁₀-alkyl optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms and/or can be interrupted by one or more =C=O groups in the ring and/or optionally one or more possible double bonds can be contained in the ring,

R⁴ stands for hydrogen, halogen or C₁-C₄-alkyl,
R⁶, R⁷, R⁸,
R⁹, R¹⁰
and R¹¹, in each case independently of one another, stand for hydrogen or for C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkinyl, C₃-C₁₀-cycloalkyl, C₃-C₁₂-aryl or C₃-

C_{18} -heteroaryl that is optionally substituted in one or more places in the same way or differently with hydroxy, halogen, C_1 - C_{12} -alkoxy, C_1 - C_6 -alkylthio, amino, cyano, C_1 - C_6 -alkyl, $-NH-(CH_2)_p-C_3-C_{10}$ -cycloalkyl, C_3-C_{10} -cycloalkyl, C_1-C_6 -hydroxyalkyl, C_2-C_6 -alkenyl, C_2-C_6 -alkinyl, C_1-C_6 -alkoxy- C_1-C_6 -alkyl, $-NHC_1-C_6$ -alkyl, $-N(C_1-C_6$ -alkyl) $_2$, $-SO(C_1-C_6$ -alkyl), $-SO_2(C_1-C_6$ -alkyl), C_1-C_6 -alkanoyl, $-CONR^8R^9$, $-COR^{10}$, C_1-C_6 -alkylOAc, carboxy, C_3-C_{12} -aryl, C_3-C_8 -heteroaryl, $-(CH_2)_p-C_3-C_{12}$ -aryl, $-(CH_2)_p-C_3-C_{18}$ -heteroaryl, phenyl- $(CH_2)_p-R^{10}$, $-(CH_2)_pPO_3(R^{10})_2$ or with the group $-NR^8R^9$, and the phenyl, C_3-C_{10} -cycloalkyl, C_3-C_{12} -aryl, C_3-C_{18} -heteroaryl, $-(CH_2)_p-C_3-C_{12}$ -aryl and $-(CH_2)_p-C_3-C_{18}$ -heteroaryl itself optionally can be substituted in one or more places in the same way or differently with halogen, hydroxy, C_1-C_6 -alkyl, C_1-C_6 -alkoxy, or with the group $-CF_3$ or $-OCF_3$, and the ring of the C_3-C_{10} -cycloalkyl and the C_1-C_{10} -alkyl optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms and/or can be interrupted by one or more $=C=O$ groups in the ring and/or optionally one or more possible double bonds can be contained in the ring,

m stands for 0 to 8, and

n and p stand for 0 to 6, as well as isomers, diastereomers, enantiomers and salts thereof.

2. (Original) Compounds of general formula (I), according to claim 1, in which

A stands for phenylene or thiophenylene,

B stands for a bond or for C_1-C_{12} -alkylene, C_2-C_{12} -alkenylene, C_2-C_{12} -

alkinylene, C₃-C₈-cycloalkylene, C₃-C₁₂-heterocycloalkylene, C₃-C₁₂-arylene or C₃-C₁₈-heteroarylene that is optionally substituted in one or more places in the same way or differently with hydroxy, halogen, cyano, nitro, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkinyl, C₃-C₁₀-cycloalkyl, C₁-C₆-hydroxyalkyl, C₃-C₁₂-aryl, C₃-C₁₈-heteroaryl, -(CH₂)_p-C₃-C₁₂-aryl, -(CH₂)_p-C₃-C₁₈-heteroaryl, phenyl-(CH₂)_p-R¹⁰, -(CH₂)_pPO₃(R¹⁰)₂, -(CH₂)_pSO₃R⁸ or with the group -NR⁸R⁹, -NR⁸COR⁹, -NR⁸CSR⁹, -NR⁸SOR⁹, -NR⁸SO₂R⁹, -NR⁸CONR⁸R⁹, -NR⁸COOR⁹, -NR⁸C(NH)NR⁹R¹⁰, -NR⁸CSNR⁹R¹⁰, -NR⁸SONR⁹R¹⁰, -NR⁸SO₂NR⁹R¹⁰, -COR⁸, -CSR⁸, -S(O)R⁸, -S(O)₂R⁸, -S(O)₂NR⁸R⁹, -SO₃R⁸, -CO₂R⁸, -CONR⁸R⁹, -CSNR⁸R⁹, -SR⁸ or -CR⁸(OH)-R⁹,

X and Y, in each case independently of one another, stand for oxygen, sulfur or for the group -NR¹¹-, -NR¹¹(CH₂)-, -NR¹¹O-, -ONR¹¹-, =CR⁶R⁷, =C=O, =C=S, =SO, =SO₂, -C(O)O-, -OC(O)-, -S(O)O-, -OS(O)-, -S(O)₂O-, -OS(O)₂-, -CONR⁸-, -N(COR⁸)-, -N(COOR⁸)-, -N(CONR⁸R⁹)-, -NR⁸CO-, -OCONR⁸-, -NR⁸C(O)O-, -CSNR⁸-, -NR⁸CS-, -OCSNR⁸-, -NR⁸CSO-, -SONR⁸-, -NR⁸SO-, -SO₂NR⁸-, -S(O)₂N(COR⁸)-, -NR⁸SO₂-, -NR⁸CONR⁹-, -NR⁸CSNR⁹-, -NR⁸SONR⁹-, -NR⁸SO₂NR⁹-, -NR⁸C(O)NR⁹- or -NR⁸C(S)NR⁹-,

R¹ and R⁵, in each case independently of one another, stand for hydrogen, hydroxy, halogen, nitro, cyano, C₁-C₆-alkyl, C₁-C₆-alkenyl, C₁-C₆-alkinyl, C₃-C₁₀-cycloalkyl, C₃-C₁₂-aryl, C₃-C₁₈-heteroaryl or for the group -C₁-C₆-alkyloxy- C₁-

$\text{C}_6\text{-alkyloxy}$, $-(\text{CH}_2)_p\text{-C}_3\text{-C}_{12}\text{-aryl}$, $-(\text{CH}_2)_p\text{-C}_3\text{-C}_{18}\text{-heteroaryl}$, phenyl- $(\text{CH}_2)_p\text{-R}^{10}$, $-(\text{CH}_2)_p\text{PO}_3(\text{R}^{10})_2$, $-\text{NR}^8\text{R}^9$, $-\text{NR}^8\text{COR}^9$, $-\text{NR}^8\text{CSR}^9$, $-\text{NR}^8\text{SOR}^9$, $-\text{NR}^8\text{SO}_2\text{R}^9$, $-\text{NR}^8\text{CONR}^9\text{R}^{10}$, $-\text{NR}^8\text{COOR}^9$, $-\text{NR}^8\text{C}(\text{NH})\text{NR}^9\text{R}^{10}$, $-\text{NR}^8\text{CSNR}^9\text{R}^{10}$, $-\text{NR}^8\text{SONR}^9\text{R}^{10}$, $-\text{NR}^8\text{SO}_2\text{NR}^9\text{R}^{10}$, $-\text{COR}^8$, $-\text{CSR}^8$, $-\text{S}(\text{O})\text{R}^8$, $-\text{S}(\text{O})(\text{NH})\text{R}^8$, $-\text{S}(\text{O})_2\text{R}^8$, $-\text{S}(\text{O})_2\text{NR}^8\text{R}^9$, $-\text{S}(\text{O})_2\text{N=CH-NR}^8\text{R}^9$, $-\text{SO}_3\text{R}^8$, $-\text{CO}_2\text{H}$, $-\text{CO}_2\text{R}^8$, $-\text{CONR}^8\text{R}^9$, $-\text{CSNR}^8\text{R}^9$, $-\text{SR}^8$ or $-\text{CR}^8(\text{OH})\text{-R}^9$, or for $\text{C}_1\text{-C}_{10}\text{-alkyl}$, $\text{C}_2\text{-C}_{10}\text{-alkenyl}$, $\text{C}_2\text{-C}_{10}\text{-alkinyl}$, $\text{C}_3\text{-C}_{10}\text{-cycloalkyl}$, $\text{C}_3\text{-C}_{12}\text{-aryl}$ or $\text{C}_3\text{-C}_{18}\text{-heteroaryl}$ that is substituted in one or more places in the same way or differently with hydroxy, $\text{C}_1\text{-C}_6\text{-alkoxy}$, halogen, phenyl or with the group $-\text{NR}^3\text{R}^4$, and the phenyl, $\text{C}_3\text{-C}_{10}\text{-cycloalkyl}$, $\text{C}_3\text{-C}_{12}\text{-aryl}$, $\text{C}_3\text{-C}_{18}\text{-heteroaryl}$, $-(\text{CH}_2)_p\text{-C}_3\text{-C}_{12}\text{-aryl}$ and $-(\text{CH}_2)_p\text{-C}_3\text{-C}_{18}\text{-heteroaryl}$ itself optionally can be substituted in one or more places in the same way or differently with halogen, hydroxy, $\text{C}_1\text{-C}_6\text{-alkyl}$, $\text{C}_1\text{-C}_6\text{-alkoxy}$, or with the group $-\text{CF}_3$ or

-OCF₃, and the ring of C₃-C₁₀-cycloalkyl and the C₁-C₁₀-alkyl optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms and/or can be interrupted by one or more =C=O groups in the ring and/or optionally one or more double bonds can be contained in the ring,

R^2 stands for hydrogen or C₁-C₁₀-alkyl,

C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkoxy-C₁-C₆-alkyl, -NHC₁-C₆-alkyl, -N(C₁-C₆-alkyl)₂, -SO(C₁-C₆-alkyl), -SO₂(C₁-C₆-alkyl), C₁-C₆-alkanoyl, -CONR⁸R⁹, -COR¹⁰, C₁-C₆-alkylOAc, carboxy, C₃-C₁₂-aryl, C₃-C₁₈-heteroaryl, -(CH₂)_p-C₃-C₁₂-aryl, -(CH₂)_p-C₃-C₁₈-heteroaryl, phenyl-(CH₂)_p-R¹⁰, -(CH₂)_pPO₃(R¹⁰)₂ or for the group -NR⁸R⁹, or for C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkinyl, C₃-C₁₀-cycloalkyl, C₃-C₁₂-aryl or C₃-C₁₈-heteroaryl that is substituted in one or more places in the same way or differently with hydroxy, halogen, C₁-C₆-alkoxy, C₁-C₆-alkylthio, amino, cyano, C₁-C₆-alkyl, -NH-(CH₂)_p-C₃-C₁₀-cycloalkyl, C₃-C₁₀-cycloalkyl, C₁-C₆-hydroxyalkyl, C₂-C₆-alkenyl, C₂-C₆-alkinyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkoxy-C₁-C₆-alkyl, -NHC₁-C₆-alkyl, -N(C₁-C₆-alkyl)₂, -SO(C₁-C₆-alkyl), -SO₂(C₁-C₆-alkyl), C₁-C₆-alkanoyl, -CONR⁸R⁹, -COR¹⁰, C₁-C₆-alkylOAc, carboxy, C₃-C₁₂-aryl, C₃-C₁₈-heteroaryl, -(CH₂)_p-C₃-C₁₂-aryl, -(CH₂)_p-C₃-C₁₈-heteroaryl, phenyl-(CH₂)_p-R¹⁰, -(CH₂)_pPO₃(R¹⁰)₂ or with the group -NR⁸R⁹; and the phenyl, C₃-C₁₀-cycloalkyl, C₃-C₁₂-aryl, C₃-C₁₈-heteroaryl, -(CH₂)_p-C₃-C₁₂-aryl and -(CH₂)_p-C₃-C₁₈-heteroaryl itself optionally can be substituted in one or more places in the same way or differently with halogen, hydroxy, C₁-C₆-alkyl, C₁-C₆-alkoxy, or with the group -CF₃ or -OCF₃, and the ring of the C₃-C₁₀-cycloalkyl and the C₁-C₁₀-alkyl optionally can be interrupted by one or more nitrogen, oxygen, and/or sulfur atoms and/or can be interrupted by one or more =C=O groups in the ring and/or optionally one or more possible double bonds can be contained in the ring,

R⁴ stands for hydrogen, halogen or C₁-C₄-alkyl,

R^6 , R^7 , R^8 ,

R^9 , R^{10}

and R^{11} , in each case independently of one another, stand for hydrogen or for

C_1 - C_{10} -alkyl, C_2 - C_{10} -alkenyl, C_2 - C_{10} -alkinyl, C_3 - C_{10} -cycloalkyl, C_3 - C_{12} -aryl or C_3 - C_{18} -heteroaryl that is optionally substituted in one or more places in the same way or differently with hydroxy, halogen, C_1 - C_{12} -alkoxy, C_1 - C_6 -alkylthio, amino, cyano, C_1 - C_6 -alkyl, $-NH-(CH_2)_p-C_3-C_{10}$ -cycloalkyl, C_3-C_{10} -cycloalkyl, C_1-C_6 -hydroxyalkyl, C_2-C_6 -alkenyl, C_2-C_6 -alkinyl, C_1-C_6 -alkoxy- C_1-C_6 -alkyl, C_1-C_6 -alkoxy- C_1-C_6 -alkoxy- C_1-C_6 -alkyl, $-NHC_1-C_6$ -alkyl, $-N(C_1-C_6$ -alkyl) $_2$, $-SO(C_1-C_6$ -alkyl), $-SO_2(C_1-C_6$ -alkyl), C_1-C_6 -alkanoyl, $-CONR^8R^9$, $-COR^{10}$, C_1-C_6 -alkylOAc, carboxy, C_3-C_{12} -aryl, C_3-C_8 -heteroaryl, $-(CH_2)_p-C_3-C_{12}$ -aryl, $-(CH_2)_p-C_3-C_{18}$ -heteroaryl, phenyl- $(CH_2)_p-R^{10}$, $-(CH_2)_pPO_3(R^{10})_2$ or with the group $-NR^8R^9$, and the phenyl, C_3-C_{10} -cycloalkyl, C_3-C_{12} -aryl, C_3-C_{18} -heteroaryl, $-(CH_2)_p-C_3-C_{12}$ -aryl and $-(CH_2)_p-C_3-C_{18}$ -heteroaryl itself optionally can be substituted in one or more places in the same way or differently with halogen, hydroxy, C_1-C_6 -alkyl, C_1-C_6 -alkoxy, or with the group $-CF_3$ or $-OCF_3$, and the ring of C_3-C_{10} -cycloalkyl and the C_1-C_{10} -alkyl optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or can be interrupted by one or more $=C=O$ groups in the ring and/or optionally one or more possible double bonds can be contained in the ring,

m stands for 0 to 8, and

n and p stand for 0 to 6,

as well as isomers, diastereomers, enantiomers and salts thereof..

3. (Currently Amended) Compounds of general formula (I), according to claim 1
~~claims 1 and 2~~, in which

A stands for phenylene or thiophenylene,

B stands for a bond or for C₁-C₁₂-alkylene, C₃-C₈-cycloalkylene or C₃-C₁₂-arylene that is optionally substituted in one or more places in the same way or differently with hydroxy, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl or -(CH₂)_pSO₃R⁸,

X and Y, in each case independently of one another, stand for oxygen or for the group -NR¹¹-, -NR¹¹(CH₂)-, -CONR⁸-, -SO₂NR⁸- or -NR⁸CONR⁹-,

R¹ and R⁵, in each case independently of one another, stand for hydrogen, halogen, nitro, C₁-C₆-alkyl, or for -NR⁸R⁹, -C₁-C₆-alkyloxy-C₁-C₆-alkyloxy or -S(O)₂NR⁸R⁹,

R² stands for hydrogen,

R³ stands for hydrogen, halogen, cyano, C₁-C₁₀-alkyl or -CONR⁸R⁹,

R⁴ stands for hydrogen,

R⁸,

R⁹

and R¹¹, in each case independently of one another, stand for hydrogen or for

C₁-C₁₀-alkyl,

m stands for 0 to 4, and

p stands for 0 to 6,

as well as isomers, diastereomers, enantiomers and salts thereof.

4. (Currently Amended) Compounds of general formula (I), according to claim 1 claims 1 to 3, in which

A stands for phenylene,

B stands for a bond or for C₁-C₁₂-alkylene, cyclohexylene or phenylene that is optionally substituted in one or more places in the same way or differently with hydroxy, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl or -(CH₂)SO₃R⁸,

X stands for oxygen or for the group -CONR⁸-, -SO₂NR⁸- or -NR⁸CONR⁹-,

Y stands for oxygen or for the group -NR¹¹-,

R¹ and R⁵, in each case independently of one another, stand for hydrogen, amino, halogen, nitro, C₁-C₆-alkyl, or for the group -NR⁸R⁹, -C₁-C₆-alkyloxy- C₁-C₆-alkyloxy or -S(O)₂NR⁸R⁹,

R² stands for hydrogen,

R³ stands for hydrogen, halogen, cyano, C₁-C₁₀-alkyl, or -CONR⁸R⁹,

R⁴ stands for hydrogen,

R⁸, R⁹ and R¹¹, in each case independently of one another, stand for hydrogen or for methyl or isobutyl,

m stands for 0 to 4, and

p stands for 0 to 6,

as well as isomers, diastereomers, enantiomers, and salts thereof.

5. (Currently Amended) Compounds of general formula (I), according to claim 1
~~claims 1 to 4~~, in which

- A stands for phenylene,
 - B stands for a bond or for C₁-C₁₂-alkylene that is optionally substituted in one or more places in the same way or differently with hydroxy, C₁-C₆-hydroxyalkyl or -(CH₂)SO₃R⁸,
 - X stands for oxygen or for the group -SO₂NR⁸- or -NR⁸CONR⁹- ,
 - Y stands for the group -NR¹¹-,
 - R¹ and R⁵, in each case independently of one another, stand for hydrogen, amino, halogen, nitro or for the group -S(O)₂NR⁸R⁹,
 - R² stands for hydrogen,
 - R³ stands for halogen or cyano,
 - R⁴ stands for hydrogen,
 - R⁸, R⁹ and R¹¹ in each case stand for hydrogen, and
 - m stands for 0 to 4,
- as well as isomers, diastereomers, enantiomers and salts thereof.

6. (Currently Amended) Compounds of general formula (I), according to claim 1
~~claims 1 to 3~~, in which

- A stands for thiophenylene,
- B stands for a bond or for C₁-C₁₂-alkylene,
- X stands for the group -SO₂NR⁸-,
- Y stands for the group -NR¹¹-,

R^3 stands for halogen,


R^1, R^2, R^4, R^5 ,

R^8, R^9 and R^{11} in each case stand for hydrogen,

m stands for 0 to 2,

as well as isomers, diastereomers, enantiomers and salts thereof.

7. (Original) Compounds of general formula I



(I),

in which

- A stands for C₃-C₁₂-arylene or C₃-C₁₈-heteroarylene,
- B stands for a bond or for C₁-C₁₂-alkylene, C₂-C₁₂-alkenylene, C₂-C₁₂-alkinylene, C₃-C₈-cycloalkylene, C₃-C₁₂-heterocycloalkylene, C₃-C₁₂-arylene or C₃-C₁₈-heteroarylene that is optionally substituted in one or more places in the same way or differently with hydroxy, halogen, cyano, nitro, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkinyl, C₃-C₁₀-cycloalkyl, C₁-C₆-hydroxyalkyl, C₃-C₁₂-aryl, C₃-C₁₈-heteroaryl, -(CH₂)_p-C₃-C₁₂-aryl, -(CH₂)_p-C₃-C₁₈-heteroaryl, phenyl-(CH₂)_p-R¹⁰, -(CH₂)_pPO₃(R¹⁰)₂ or with the group-NR⁸R⁹, -NR⁸COR⁹, -NR⁸CSR⁹, -NR⁸SOR⁹, -NR⁸SO₂R⁹, -NR⁸CONR⁸R⁹, -NR⁸COOR⁹, -NR⁸C(NH)NR⁹R¹⁰, -NR⁸CSNR⁹R¹⁰, -NR⁸SONR⁹R¹⁰, -NR⁸SO₂NR⁹R¹⁰, -COR⁸, -CSR⁸, -S(O)R⁸, -S(O)₂R⁸, -S(O)₂NR⁸R⁹, -SO₃R⁸, -CO₂R⁸, -CONR⁸R⁹, -CSNR⁸R⁹, -SR⁸ or

-CR⁸(OH)-R⁹,

X and Y, in each case independently of one another, stand for oxygen, sulfur or

for the group =NR¹¹, -NR¹¹O-, -ONR¹¹-, =CR⁶R⁷, =C=O, =C=S, =SO, =SO₂, -C(O)O-, -OC(O)-, -S(O)O-, -OS(O)-, -S(O)₂O-, -OS(O)₂-, -CONR⁸-, -NR⁸CO-, -OCONR⁸-, -NR⁸C(O)O-, -CSNR⁸-, -NR⁸CS-, -OCSNR⁸-, -NR⁸CSO-, -SONR⁸-, -NR⁸SO-, -SO₂NR⁸-, -NR⁸SO₂-, -NR⁸CONR⁹-, -NR⁸CSNR⁹-, -NR⁸SONR⁹-, -NR⁸SO₂NR⁹-, -NR⁸C(O)NR⁹- or -NR⁸C(S)NR⁹-,

R¹ and R⁵, in each case independently of one another, stand for hydrogen,

hydroxy, halogen, nitro, cyano, C₁-C₆-alkyl, C₁-C₆-alkenyl, C₁-C₆-alkinyl, C₃-C₁₀-cycloalkyl, C₃-C₁₂-aryl, C₃-C₁₈-heteroaryl or for the group -(CH₂)_p-C₃-C₁₂-aryl, -(CH₂)_p-C₃-C₁₈-heteroaryl, phenyl-(CH₂)_p-R¹⁰, -(CH₂)_pPO₃(R¹⁰)₂, -NR⁸R⁹, -NR⁸COR⁹, -NR⁸CSR⁹, -NR⁸SOR⁹, -NR⁸SO₂R⁹, -NR⁸CONR⁹R¹⁰, -NR⁸COOR⁹, -NR⁸C(NH)NR⁹R¹⁰, -NR⁸CSNR⁹R¹⁰, -NR⁸SONR⁹R¹⁰, -NR⁸SO₂NR⁹R¹⁰, -COR⁸, -CSR⁸, -S(O)R⁸, -S(O)₂R⁸, -S(O)₂NR⁸R⁹, -SO₃R⁸, -CO₂H, -CO₂R⁸, -CONR⁸R⁹, -CSNR⁸R⁹, -SR⁸ or -CR⁸(OH)-R⁹, or for C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkinyl, C₃-C₁₀-cycloalkyl, C₃-C₁₂-aryl or C₃-C₁₈-heteroaryl that is substituted in one or more places in the same way or differently with hydroxy, C₁-C₆-alkoxy, halogen, phenyl or with the group -NR³R⁴, and the phenyl, C₃-C₁₀-cycloalkyl, C₃-C₁₂-aryl, C₃-C₁₈-heteroaryl, -(CH₂)_p-C₃-C₁₂-aryl and -(CH₂)_p-C₃-C₁₈-heteroaryl

itself optionally can be substituted in one or more places in the same way or differently with halogen, hydroxy, C₁-C₆-alkyl, C₁-C₆-alkoxy, or with the group -CF₃ or -OCF₃, and the ring of the C₃-C₁₀-cycloalkyl and the C₁-C₁₀-alkyl optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms and/or can be interrupted by one or more =C=O groups in the ring and/or optionally one or more possible double bonds can be contained in the ring,

R² stands for hydrogen or C₁-C₁₀-alkyl,

R³ stands for hydrogen, halogen, nitro, cyano, C₁-C₁₀-alkyl, halo-C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkinyl, C₃-C₁₀-cycloalkyl, hydroxy, C₁-C₆-alkoxy, C₁-C₆-alkylthio, amino, -NH-(CH₂)_p-C₃-C₁₀-cycloalkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkoxy-C₁-C₆-alkyl, -NHC₁-C₆-alkyl, -N(C₁-C₆-alkyl)₂, -SO(C₁-C₆-alkyl), -SO₂(C₁-C₆-alkyl), C₁-C₆-alkanoyl, -CONR⁸R⁹, -COR¹⁰, C₁-C₆-alkylOAc, carboxy, C₃-C₁₂-aryl, C₃-C₁₈-heteroaryl, -(CH₂)_p-C₃-C₁₂-aryl, -(CH₂)_p-C₃-C₁₈-heteroaryl, phenyl-(CH₂)_p-R¹⁰, -(CH₂)_pPO₃(R¹⁰)₂ or for the group -NR⁸R⁹, or for C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkinyl, C₃-C₁₀-cycloalkyl, C₃-C₁₂-aryl or C₃-C₁₈-heteroaryl that is substituted in one or more places in the same way or differently with hydroxy, halogen, C₁-C₆-alkoxy, C₁-C₆-alkylthio, amino, cyano, C₁-C₆-alkyl, -NH-(CH₂)_p-C₃-C₁₀-cycloalkyl, C₃-C₁₀-cycloalkyl, C₁-C₆-hydroxyalkyl, C₂-C₆-alkenyl, C₂-C₆-alkinyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkoxy-C₁-C₆-alkyl, -NHC₁-C₆-alkyl, -N(C₁-C₆-alkyl)₂, -SO(C₁-C₆-alkyl), -SO₂(C₁-C₆-alkyl), C₁-C₆-alkanoyl, -CONR⁸R⁹, -COR¹⁰, C₁-C₆-alkylOAc,

, carboxy, C₃-C₁₂-aryl, C₃-C₁₈-heteroaryl, -(CH₂)_p- C₃-C₁₂-aryl, -(CH₂)_p- C₃-C₁₈-heteroaryl, phenyl-(CH₂)_p-R¹⁰, -(CH₂)_pPO₃(R¹⁰)₂ or with the group -NR⁸R⁹, and the phenyl, C₃-C₁₀-cycloalkyl, C₃-C₁₂-aryl, C₃-C₁₈-heteroaryl, -(CH₂)_p-C₃-C₁₂-aryl and -(CH₂)_p-C₃-C₁₈-heteroaryl itself optionally can be substituted in one or more places in the same way or differently with halogen, hydroxy, C₁-C₆-alkyl, C₁-C₆-alkoxy, or with the group -CF₃ or -OCF₃, and the ring of the C₃-C₁₀-cycloalkyl and the C₁-C₁₀-alkyl optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms and/or can be interrupted by one or more =C=O groups in the ring and/or optionally one or more possible double bonds can be contained in the ring,

R⁴ stands for hydrogen, halogen or C₁-C₄-alkyl,

R⁶, R⁷, R⁸,

R⁹, R¹⁰

and R¹¹, in each case independently of one another, stand for hydrogen or for C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₂-C₁₀-alkinyl, C₃-C₁₀-cycloalkyl, C₃-C₁₂-aryl or C₃-C₁₈-heteroaryl that is optionally substituted in one or more places in the same way or differently with hydroxy, halogen, C₁-C₁₂-alkoxy, C₁-C₆-alkylthio, amino, cyano, C₁-C₆-alkyl, -NH-(CH₂)_p-C₃-C₁₀-cycloalkyl, C₃-C₁₀-cycloalkyl, C₁-C₆-hydroxyalkyl, C₂-C₆-alkenyl, C₂-C₆-alkinyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkoxy-C₁-C₆-alkyl, -NHC₁-C₆-alkyl, -N(C₁-C₆-alkyl)₂, -SO(C₁-C₆-alkyl), -SO₂(C₁-C₆-alkyl), C₁-C₆-alkanoyl, -CONR⁸R⁹, -COR¹⁰, C₁-C₆-alkylOAc, carboxy, C₃-C₁₂-aryl, C₃-C₈-heteroaryl, -(CH₂)_p- C₃-C₁₂-aryl, -(CH₂)_p- C₃-C₁₈-

heteroaryl, phenyl-(CH₂)_p-R¹⁰, -(CH₂)_pPO₃(R¹⁰)₂ or with the group -NR⁸R⁹, and the phenyl, C₃-C₁₀-cycloalkyl, C₃-C₁₂-aryl, C₃-C₁₈-heteroaryl, -(CH₂)_p-C₃-C₁₂-aryl and -(CH₂)_p-C₃-C₁₈-heteroaryl itself optionally can be substituted in one or more places in the same way or differently with halogen, hydroxy, C₁-C₆-alkyl, C₁-C₆-alkoxy, or with the group -CF₃ or -OCF₃, and the ring of the C₃-C₁₀-cycloalkyl and the C₁-C₁₀-alkyl optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or can be interrupted by one or more =C=O groups in the ring and/or optionally one or more possible double bonds can be contained in the ring,

m stands for 0 to 8, and

n and p stand for 0 to 6,

as well as isomers, diastereomers, enantiomers and salts thereof.

8. (Original) Compounds of general formula (I), according to claim 7, in which

A stands for phenylene or thiophenylene,

B stands for C₁-C₁₂-alkylene that is optionally substituted in one or more places in the same way or differently with hydroxy, C₁-C₆-alkyl or C₁-C₆-hydroxyalkyl,

X and Y, in each case independently of one another, stand for oxygen or for the group =NR¹¹, -NR⁸CO-, -CONR⁸-, -SO₂NR⁸- or -NR⁸SO₂-,

R¹ and R⁵, in each case independently of one another, stand for hydrogen or for the group -SO₂NR⁸R⁹,

R² stands for hydrogen,

R^3 stands for hydrogen, halogen, cyano, C_1-C_{10} -alkyl or for the group
 $-CONR^8R^9$,

R^4 stands for hydrogen,

R^8 and R^{11} stand for hydrogen,

R^9 stands for hydrogen or C_1-C_6 -alkyl,


m stands for 0 to 8, and

n stands for 0 to 6,

as well as isomers, diastereomers, enantiomers and salts thereof.

9. (Original) Process for the production of the compounds of general formula I according to the invention, wherein either


a) compounds of general formula VIII



in which R^1 , R^2 , R^3 , R^4 , R^5 , X , Y , A , B , m and n have the meanings that are indicated in general formula I, and L stands for a leaving group, are cyclized with a suitable acid to compounds of


general formula I, or


b) the acyclic precursors of general formula (IX)




in which R^1 , R^3 , R^4 , R^5 , X , Y , A , B , m and n have the meanings that are indicated in general formula I, and L stands for a leaving group, are first reduced to amine in a suitable solvent and a suitable reducing agent at 0°C until reflux takes place and then the intermediately formed amine is cyclized to the compounds of general formula I.

10. (Original) Compounds of general formula (II), (III), (IV), (V), (VI) or (VII)








(III)



(IV)




(V)



oder

[or]

in which R¹, R², R³, R⁴, R⁵, R⁸, R¹¹, A, B and m have the meanings that are indicated in general formula I and D stands for -NH₂, NAc or -NO₂, q stands for 1 to 12, U stands for group -OH, -CO₂H, -CO₂-C₁-C₆-alkyl, -SO₂Cl, -SO₂F, -SO₃H or



and W stands for the group -OH, -OH, -CO₂H, -CO₂-C₁-C₆-alkyl, -SO₂Cl, -SO₂F or -SO₃H,

as well as isomers, diastereomers, enantiomers and salts thereof.


11. (Original) Compounds of general formula (II), (III), (IV), (V), (VI) or (VII) according

to claim 10, in which

A stands for phenylene or thiophenylene, and

R¹, R², R³, R⁴, R⁵, R⁸, R¹¹ and m have the meanings that are indicated in general formula I, and D stands for -NH₂, -NAc or -NO₂, q stands for 1 to 12,

U stands for the group -OH, -CO₂H, -CO₂-C₁-C₆-Alkyl, -SO₂Cl, -SO₂F, -SO₃H or



W stands for the group -OH, -OH, -CO₂H, -CO₂-C₁-C₆-alkyl, -SO₂Cl, -SO₂F or -SO₃H,

as well as isomers, diastereomers, enantiomers and salts thereof.

12. (Currently Amended) Use of the compounds of general formula I, according to claim 1 claims 1 to 8, for the production of a pharmaceutical agent for the treatment of cancer, angiofibroma, arthritis, eye diseases, autoimmune diseases, chemotherapy agent-induced alopecia and mucositis, Crohn's disease, endometriosis, fibrotic diseases, hemangioma, cardiovascular diseases, infectious diseases, nephrological diseases, chronic and acute neurodegenerative diseases, as well as injuries to nerve tissue, viral infections, for inhibiting reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents, as immunosuppressive agents, for supporting scar-free healing, in the case of senile keratosis and contact dermatitis.

13. (Original) Use according to claim 12, wherein
cancer is defined as solid tumors, tumor or metastasis growth, Kaposi's sarcoma,
Hodgkin's disease, and leukemia;
arthritis is defined as rheumatoid arthritis;
eye diseases are defined as diabetic retinopathy, and neovascular glaucoma;
auto-immune diseases are defined as psoriasis, alopecia and multiple sclerosis;
fibrotic diseases are defined as cirrhosis of the liver, mesangial cell proliferative diseases,
and arteriosclerosis;
infectious diseases are defined as diseases that are caused by unicellular parasites;
cardiovascular diseases are defined as stenoses, such as, e.g., stent-induced restenoses,
arterioscleroses, and restenoses;
nephrological diseases are defined as glomerulonephritis, diabetic nephropathy, malignant
nephrosclerosis, thrombotic microangiopathic syndrome, transplant rejections and glomerulopathy;
chronic neurodegenerative diseases are defined as Huntington's disease, amyotrophic
lateral sclerosis, Parkinson's disease, AIDS dementia and Alzheimer's disease;
acute neurodegenerative diseases are defined as ischemias of the brain and neurotraumas;
and viral infections are defined as cytomegalic infections, herpes, hepatitis B or C, and
HIV diseases.

14. (Currently Amended) Pharmaceutical agents that contain at least one compound
according to claim 1 one of claims 1 to 8.

15. (Original) Pharmaceutical agents according to claim 14 for treating cancer,
angiofibroma, arthritis, eye diseases, autoimmune diseases, chemotherapy agent-induced alopecia

and mucositis, Crohn's disease, endometriosis, fibrotic diseases, hemangioma, cardiovascular diseases, infectious diseases, nephrological diseases, chronic and acute neurodegenerative diseases, as well as injuries to nerve tissue, and viral infections, and for inhibiting reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents, and as immunosuppressive agents, and for supporting scar-free healing, and in the case of senile keratosis and contact dermatitis.

16. (Original) Pharmaceutical agent for use according to claim 15, whereby cancer is defined as solid tumors, tumor or metastasis growth, Kaposi's sarcoma, Hodgkin's disease, and leukemia;

arthritis is defined as rheumatoid arthritis;

eye diseases are defined as diabetic retinopathy, and neovascular glaucoma;

auto-immune diseases are defined as psoriasis, alopecia and multiple sclerosis;

fibrotic diseases are defined as cirrhosis of the liver, mesangial cell proliferative diseases, and arteriosclerosis;

infectious diseases are defined as diseases that are caused by unicellular parasites;

cardiovascular diseases are defined as stenoses, such as, e.g., stent-induced restenoses, arterioscleroses, and restenoses;

nephrological diseases are defined as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy;

chronic neurodegenerative diseases are defined as Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, AIDS dementia and Alzheimer's disease;

acute neurodegenerative diseases are defined as ischemias of the brain and neurotraumas;

and viral infections are defined as cytomegalic infections, herpes, hepatitis B or C, and HIV diseases.

17. (Currently Amended) Compounds according to claim 1 ~~claims 1 to 8~~ and pharmaceutical agents ~~containing there according to one of claims 14 to 16~~ with suitable formulation substances and vehicles.

18. (Currently Amended) Use of the compounds of general formula I and the pharmaceutical agents, according to claim 1 ~~one of claims 1 to 8 and 14~~, as inhibitors of the cyclin-dependent kinases.

19. (Original) Use according to claim 17, wherein the kinase is CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8 or CDK9.

20. (Currently Amended) Use of the compounds of general formula I and the pharmaceutical agents, according to claim 1 ~~one of claims 1 to 8 and 14~~, as inhibitors of the glycogen-synthase-kinase (GSK-3 β).

21. (Currently Amended) Use of the compounds of general formula I and the pharmaceutical agents, according to claim 1 ~~one of claims 1 to 8 and 14~~, as inhibitors of the VEGF-receptor tyrosine kinases.

22. (Currently Amended) Use of the compounds of general formula I and the pharmaceutical agents, according to claim 1 ~~one of claims 1 to 8 and 14~~, as inhibitors of the cyclin-dependent kinases and the VEGF-receptor tyrosine kinases.

23. (Currently Amended) Use of the compounds of general formula I, according to claim 1 ~~one of claims 1 to 8~~, in the form of a pharmaceutical preparation for enteral, parenteral and oral administration.